Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2020

  1. 04/02/2020
    MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
  2. 13/01/2020
    MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
  3. 13/01/2020
    MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
    No download available

2019

  1. 30/12/2019
    MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
  2. 27/12/2019
    First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
  3. 12/12/2019
    MorphoSys AG: Corporate Calendar 2020
  4. 20/11/2019
    Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure
  5. 18/11/2019
    MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
  6. 15/11/2019
    MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice
  7. 11/11/2019
    Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2020

  1. 13/01/2020
    MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
    No download available

2019

  1. 18/11/2019
    Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
    No download available
  2. 29/10/2019
    MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
    No download available
  3. 28/10/2019
    MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
    No download available
  4. 03/07/2019
    Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
    No download available
  5. 24/06/2019
    Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  6. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  7. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  8. 19/02/2019
    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
    No download available
  9. 26/01/2019
    Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
    No download available

Pages

Presentations
and conferences

Wednesday, January 15, 2020 - 10:30pm
Webcast: 38th Annual J.P. Morgan Healthcare Conference

Dr. Jean-Paul Kress presented the Company at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, USA, on January 15, 2020.

Go to replay of the Webcast...

DocumentFile info
Company Update2.41 MB

Archive

Date
Title
MP3

2020

  1. 01/15/2020

    Webcast: 38th Annual J.P. Morgan Healthcare Conference

  2. 01/13/2020

    Joint Conference Call MorphoSys and Incyte on the Global Collaboration and License Agreement for Tafasitamab

2019

  1. 12/03/2019

    31st Annual Piper Jaffray Healthcare Conference

  2. 11/25/2019

    Presentation: German Eigenkapitalforum

  3. 10/30/2019

    Conference Call and Webcast: Q3 2019 Financial Results

  4. 09/25/2019

    Presentation: 8th Annual Goldman Sachs and Berenberg German Corporate Conference

  5. 08/27/2019

    Presentation: Commerzbank Sector Conference 2019

  6. 08/07/2019

    Conference Call and Webcast: Q2 2019 Financial Results

  7. 06/25/2019

    Webcast: Meet the Team

  8. 06/22/2019

    Presentation: ICML in Lugano

  9. 06/12/2019

    Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

  10. 06/06/2019

    Presentation: dbAccess

  11. 06/05/2019

    Webcast: Jefferies Healthcare Conference

  12. 05/20/2019

    Conference call: Q&A session on the headline data of tafasitamab (MOR208)

  13. 05/08/2019

    Conference Call and Webcast: Q1 2019 Financial Results

  14. 04/26/2019

    Presentation: Class of 2018 Biotech IPOs Investor Day

  15. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  16. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  17. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

Pages

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".